<i id='8EAE0F31D7'><strike id='8EAE0F31D7'><tt id='8EAE0F31D7'><pre id='8EAE0F31D7'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Sports medicine is finally prioritizing gender equality 
The U.S. needs a new definition of substance use “recovery” 
Heart attack and stroke risk calculators need revising 
Heat waves linked to early deliveries, preterm births in new study 
Medicare details structure of new drug price negotiation program 
Biohaven protein 
The high cost of giving birth even with insurance 
The aspartame in Diet Coke probably isn’t giving you cancer 
Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies 
Average age of first period drops to 11.9 years, study shows 
Medical leaders decry Supreme Court decision on affirmative action 
Wisconsin governor employs partial veto to fund schools for 4 centuries 
Peter Hotez and the public health issue of online harassment 
Dark money group runs ads on China biotech bill 
Hollywood unions extend contract negotiations for actors 
